Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0
|
作者：
Chen, L.
Shiah, H. S.
Chen, C. Y.
Lin, Y. J.
Lin, P. W.
Su, W. C.
Chang, J. Y.
机构：
[1] Natl Hlth Res Inst, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Tainan 70428, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4587
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Molecular combined therapy in hepatocellular carcinoma (HCC) with AEE788 (EGFR/HER2/VEGFR inhibitor) and RAD001, everolimus (MTOR inhibitor): Antineoplastic activity in a xenograft model of HCC
    Villanueva, Augusto
    Newell, Philippa
    Peix, Judit
    Di Feo, Analisa
    Van Laarhoven, Stijn
    Thung, Swan
    Isabel, Fiel
    Yea, Steven
    Roayaie, Sasan
    Schwartz, Myron
    Martignetti, John
    Friedman, Scott L.
    Llovet, Josep M.
    HEPATOLOGY, 2007, 46 (04) : 529A - 529A
  • [32] Phase II trial of the oral mTOR inhibitor everolimus (RAD001) for patients with relapsed or refractory lymphoma
    Johnston, P. B.
    Ansell, S. M.
    Colgan, J. P.
    Habermann, T. M.
    Inwards, D. J.
    Markovic, S. N.
    Micallef, I. N.
    Porrata, L. F.
    LaPlant, B. R.
    Geyer, S. M.
    Witzig, T. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    Ueno, Hideki
    Nakachi, Kohei
    Morizane, Chigusa
    Kondo, Shunsuke
    Shimizu, Satoshi
    Kojima, Yasushi
    Suzuki, Takuya
    Tamai, Toshiyuki
    O'Brien, James P.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Thomas Decker
    Michael Sandherr
    Katharina Goetze
    Madlen Oelsner
    Ingo Ringshausen
    Christian Peschel
    Annals of Hematology, 2009, 88 : 221 - 227
  • [35] A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
    Decker, Thomas
    Sandherr, Michael
    Goetze, Katharina
    Oelsner, Madlen
    Ringshausen, Ingo
    Peschel, Christian
    ANNALS OF HEMATOLOGY, 2009, 88 (03) : 221 - 227
  • [36] Phase I/II study of S-1 in patients (pts) with advanced hepatocellular carcinoma (HCC): Results of phase I part - Correlation between pharmacokinetics (PK) and hepatic dysfunction
    Furuse, J.
    Okusaka, T.
    Ishii, H.
    Nakachi, K.
    Suzuki, E.
    Shimizu, S.
    Ueno, H.
    Ikeda, M.
    Morizane, C.
    Ogura, T.
    EJC SUPPLEMENTS, 2007, 5 (04): : 275 - 275
  • [37] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [38] Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC)
    Blaszkowsky, L. S.
    Abrams, T. A.
    Miksad, R. A.
    Zheng, H.
    Meyerhardt, J. A.
    Schrag, D.
    Kwak, E. L.
    Fuchs, C.
    Ryan, D. P.
    Zhu, A. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): Phase I safety and pharmacokinetic (PK) study
    Finn, Richard S.
    Blumenschein, George R.
    Tolcher, Anthony W.
    Leong, Stephen
    Boix, Oliver
    Diefenbach, Konstanze
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [40] Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
    Wang, Emilie
    Kim, Dae Won
    Mahipal, Amit
    Chen, Dung-Tsa
    Cao, Biwei
    Masawi, Fadzai
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345